PDCD1 and adrenal cortex carcinoma: Immune checkpoint inhibitors such as anti-CTLA-4 antibodies and anti-programmed cell death protein 1 (anti-PD-1) antibodies and anti-PD-ligand 1 (PD-L1) have demonstrated antitumor activity in various solid malignancies, which has generated interest in their use for adrenocortical carcinoma patients (21).